Kivelev Juri, Göhre Felix, Niemelä Mika, Hernesniemi Juha
Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Topeliuksenkatu 5, 00260, Helsinki, Finland,
Acta Neurochir (Wien). 2015 Sep;157(8):1353-7; discussion 1357. doi: 10.1007/s00701-015-2473-x. Epub 2015 Jul 3.
We analyze our experience of using TachoSil® (Takeda Austria GmbH: Linz, Austria) in microneurosurgical procedures as a hemostat and also as a sealant to patch dural defects.
Beginning on January 1, 2012, we prospectively analyzed 100 consecutive surgeries where TachoSil was used. The patient group included 58 women (58 %) and 42 men (42 %); the mean age was 52 years (range, 3-85 years). Indications for surgery included removal of the tumor (53 cases; 53 %), clipping of the cerebral arterial aneurysm (31 cases; 31 %), and treatment of other pathologies, including AVM (four cases; 4 %), cavernomas (four cases; 4 %), spinal tumor, and traumatic subdural hematoma. Patients received postoperative care according to local neurosurgical department protocol, including a postoperative CT scan after each craniotomy. Primary assessment of the wound took place during the hospital stay as well as at discharge or transfer to a rehabilitation unit. Mean follow-up time was 4 months (range, 1-12 months).
None of the patients developed postoperative hematoma after craniotomy or spinal procedure. At primary assessment during hospital stay, 93 patients (93 %) had had no wound-related problems over the normal course of healing. No case registered any liquor leak from the wound, and none of the patients showed any signs of allergic response related to TachoSil usage. At the last follow-up, 96 patients (96 %) experienced uneventful wound healing, and in four patients (4 %), superficial wound infection was successfully treated with oral antibiotics.
Our results indicate that TachoSil can serve in neurosurgical practice at no additional risks. TachoSil proved to be an effective hemostat, sealant, and adhesive in either cranial or spinal procedures.
我们分析了在显微神经外科手术中使用速即纱(武田奥地利有限公司:奥地利林茨)作为止血剂以及修补硬脑膜缺损的密封剂的经验。
从2012年1月1日起,我们前瞻性地分析了连续100例使用速即纱的手术。患者组包括58名女性(58%)和42名男性(42%);平均年龄为52岁(范围3 - 85岁)。手术适应证包括肿瘤切除(53例;53%)、脑动脉瘤夹闭术(31例;31%)以及其他病变的治疗,包括动静脉畸形(4例;4%)、海绵状血管瘤(4例;4%)、脊髓肿瘤和创伤性硬膜下血肿。患者根据当地神经外科科室方案接受术后护理,包括每次开颅术后的CT扫描。伤口的初次评估在住院期间以及出院或转至康复机构时进行。平均随访时间为4个月(范围1 - 12个月)。
开颅手术或脊柱手术后,无一例患者发生术后血肿。在住院期间的初次评估中,93例患者(93%)在正常愈合过程中未出现与伤口相关的问题。没有病例记录伤口有脑脊液漏,且没有患者表现出与使用速即纱相关的过敏反应迹象。在最后一次随访时,96例患者(96%)伤口愈合顺利,4例患者(4%)的浅表伤口感染经口服抗生素成功治疗。
我们的结果表明,速即纱可用于神经外科手术,且无额外风险。在颅脑或脊柱手术中,速即纱被证明是一种有效的止血剂、密封剂和粘合剂。